KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro ...

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual ...

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity ...

CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of allergic responses by targeting the effector cell - ...

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a ...

Feeding mice a compound found in sea squirts appeared to reverse key signs of brain aging. The lipid, known as plasmalogen, ...

Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC: Rahway, New Jersey Wednesday, October 29, 2025, ...

New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as develop ...

You think the tiny socket on your telly does little. It hides practical tricks that save time, power and money. Most living rooms already have what they ...